Discontinuation, efficacy and safety of cholinesterase inhibitors for Alzheimer’s disease: a meta-analysis and meta-regression of 44 randomized clinical trials enrolling 16.245 patients

Blanco L, Castells X, Saez M, Barceló MA, Garre J, Vilalta J, Capellà D. International Journal of Neuropsychopharmacology 2017; 20(7):519-528. doi: 10.1093/ijnp/pyx012 (Impact Factor: 4.207, CLINICAL NEUROLOGY, 40/199 Q1)